ToolBeta

Peptide Benchmark System

An evidence-based scoring system for peptides, providers, and stacks across multiple dimensions. Scores are calculated from FDA status, clinical trial data, cost, safety profiles, and practical factors. Use this to compare options objectively — not as a substitute for medical advice.

Sort by:
Kisspeptin-10
GnRH Stimulator
Good75/100
Evidence Quality75/100
Cost Accessibility55/100
Safety Profile72/100
Administration60/100
WADA Compliance100/100
Mechanism Clarity85/100

Preserves HPT axis and fertility. Phase I-II data in men. Not FDA-approved. Mechanism well-understood.

Semax
Nootropic Peptide
Good73/100
Evidence Quality35/100
Cost Accessibility87/100
Safety Profile78/100
Administration80/100
WADA Compliance100/100
Mechanism Clarity55/100

Russian clinical data for cognitive impairment. Not FDA-approved. Nasal route is convenient. Limited Western trials.

GLP-1 Agonist
Good72/100
Evidence Quality100/100
Cost Accessibility0/100
Safety Profile78/100
Administration60/100
WADA Compliance100/100
Mechanism Clarity95/100

FDA-approved for obesity and T2DM. Strongest evidence base among all peptides. Expensive without insurance.

Selank
Anxiolytic Peptide
Good72/100
Evidence Quality34/100
Cost Accessibility89/100
Safety Profile80/100
Administration80/100
WADA Compliance100/100
Mechanism Clarity50/100

Russian data for anxiety. Not FDA-approved. Favorable safety. Mechanism poorly understood in Western literature.

Dual GIP/GLP-1
Good71/100
Evidence Quality100/100
Cost Accessibility0/100
Safety Profile76/100
Administration60/100
WADA Compliance100/100
Mechanism Clarity90/100

FDA-approved. Superior weight loss vs semaglutide in head-to-head trial. Less cardiovascular outcome data.

GHK-Cu
Copper Peptide
Good70/100
Evidence Quality25/100
Cost Accessibility90/100
Safety Profile82/100
Administration60/100
WADA Compliance100/100
Mechanism Clarity60/100

Strong topical evidence for skin aging. Injectable human RCTs lacking. Naturally occurring, favorable safety.

Melanocortin Agonist
Good66/100
Evidence Quality100/100
Cost Accessibility0/100
Safety Profile68/100
Administration60/100
WADA Compliance100/100
Mechanism Clarity70/100

FDA-approved for female HSDD (Vyleesi). Male ED data exists but not approved. ~40% nausea rate.

Cerebrolysin
Neurotrophic
Fair63/100
Evidence Quality100/100
Cost Accessibility10/100
Safety Profile80/100
Administration20/100
WADA Compliance100/100
Mechanism Clarity65/100

IV-only (inconvenient). Strong vascular dementia evidence. Not FDA-approved. Requires infusion center.

Epithalon
Longevity Peptide
Fair62/100
Evidence Quality25/100
Cost Accessibility82/100
Safety Profile70/100
Administration60/100
WADA Compliance100/100
Mechanism Clarity35/100

Telomerase activation claims. Small Russian studies. No replication in Western literature. Highly speculative.

Sermorelin
GHRH Analog
Fair61/100
Evidence Quality100/100
Cost Accessibility55/100
Safety Profile72/100
Administration60/100
WADA Compliance0/100
Mechanism Clarity80/100

Formerly FDA-approved for pediatric GH deficiency (discontinued). Good safety data. WADA-banned despite approval.

MOTS-c
Mitochondrial Peptide
Fair60/100
Evidence Quality25/100
Cost Accessibility70/100
Safety Profile60/100
Administration60/100
WADA Compliance100/100
Mechanism Clarity45/100

Mitochondrial-derived peptide. Animal data for metabolic health. No human RCTs. Emerging research area.

Ipamorelin
GHRP
Fair54/100
Evidence Quality34/100
Cost Accessibility88/100
Safety Profile65/100
Administration60/100
WADA Compliance0/100
Mechanism Clarity75/100

Cleanest GHRP profile — minimal cortisol/prolactin elevation. Phase I-II data. WADA-banned. No body comp RCTs.

GHRH Analog
Fair53/100
Evidence Quality100/100
Cost Accessibility0/100
Safety Profile74/100
Administration60/100
WADA Compliance0/100
Mechanism Clarity85/100

FDA-approved for HIV lipodystrophy only. Strong evidence in that population. Expensive. WADA-banned.

CJC-1295
GHRH Analog
Fair51/100
Evidence Quality33/100
Cost Accessibility85/100
Safety Profile58/100
Administration60/100
WADA Compliance0/100
Mechanism Clarity70/100

Pharmacokinetic data exists. No RCTs for body composition in healthy adults. WADA-banned. Elevates IGF-1.

BPC-157
Healing Peptide
Poor45/100
Evidence Quality25/100
Cost Accessibility86/100
Safety Profile55/100
Administration60/100
WADA Compliance0/100
Mechanism Clarity45/100

200+ animal studies, zero published human RCTs. WADA-banned. Mechanism unclear. Quality control concerns.

TB-500
Healing Peptide
Poor43/100
Evidence Quality25/100
Cost Accessibility82/100
Safety Profile50/100
Administration60/100
WADA Compliance0/100
Mechanism Clarity40/100

Thymosin Beta-4 fragment. Animal data only. WADA-banned. No human efficacy data.

Scoring Methodology

Evidence Quality: Weighted by FDA approval status + log₁₀(largest trial size). Approved drugs with large RCTs score highest.
Cost Accessibility: Linear scale against $500/month benchmark. Lower cost = higher score.
Safety Profile: Composite of known side effect severity, frequency, and reversibility. Based on published adverse event data.
Administration: Oral (100) → Nasal (80) → Subcutaneous (60) → IM (40) → IV (20).
WADA Compliance: Binary — banned = 0, allowed = 100. Based on 2026 Prohibited List.
Mechanism Clarity: How well the molecular target and downstream effects are characterized in peer-reviewed literature.

Overall scores are unweighted averages of all dimensions unless otherwise noted. You can adjust weights in the scoring API to prioritize dimensions that matter most to your use case.

Benchmark scores are for research and comparison purposes only. They do not constitute medical advice, product endorsement, or guarantee of safety or efficacy. Individual responses to peptides vary. Always consult a qualified healthcare provider before starting any peptide therapy.